Insider Activity Spotlight: Mirum Pharmaceuticals’ COO Buys Shares While the Market Stays Quiet

On March 6 2026, Peter Radović, President and Chief Operating Officer of Mirum Pharmaceuticals, executed a modest purchase of 5,912 common shares at $15.87 each, bringing his total ownership to 26,567 shares. The transaction, disclosed under Form 4, represents a 17 % increase over his prior holding as of January 21. Although the trade size is small relative to the company’s approximate market capitalization of $5.4 billion, it signals continued confidence in Mirum’s long‑term prospects.

Market Context and Share Performance

The shares closed the preceding day at $90.93, a 1.4 % decline from the prior week, following a sharp rally that lifted the stock to a 52‑week high of $109.28 in early February. Despite this volatility, the share price has remained relatively stable in the wake of the recent regulatory approvals and ongoing clinical developments that underpin the company’s valuation.

Strategic Significance of the Purchase

Radović’s conversion of 5,912 stock options—now exercisable at a strike price well below market value—into shares reduces potential dilution that would arise if the options were exercised later. By locking in ownership at current levels, the COO demonstrates a bullish endorsement: he is willing to commit capital rather than wait for a future price spike. However, the modest trade size and the company’s negative price‑to‑earnings ratio of –190.1 underscore that this signal should be weighed against broader market uncertainty and the firm’s still‑developing earnings profile.

Insider‑Trading Pattern Over the Past Three Months

Examining Radović’s activity in the preceding quarter reveals a pattern of alternating buys and sells across common stock, restricted stock units (RSUs), and performance‑restricted units. His most recent sale on January 26 of 3,143 shares at $96.19 preceded the March 6 purchase, indicating short‑term portfolio rebalancing. Historically, Radović’s trades average a 5‑10 % change in holdings, with a tendency to buy RSUs and performance units early in the year and liquidate common shares later. This “buy‑low, sell‑high” strategy aligns his interests with the company’s long‑term performance while maintaining liquidity for personal needs.

Company‑Wide Insider Activity

Other key insiders—Chief Executive Officer Christopher Peetz, Senior Vice President Global Controller Jolanda Howe, and Chief Medical Officer Joanne Quan—have also been active. Peetz recently sold 9,108 shares at $103.30 and subsequently purchased 67,000 options, suggesting a similar conversion strategy. Overall, insider activity is largely concentrated in options and RSUs, indicating executives’ confidence in Mirum’s growth trajectory while preferring the flexibility of options to manage tax and dilution impacts.

Regulatory Approvals and Pipeline Highlights

Mirum’s clinical portfolio is anchored by its lead product, Mira‑B, a novel small‑molecule inhibitor targeting the PI3K/AKT/mTOR pathway in solid tumors. On January 12, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Mira‑B in metastatic colorectal cancer, following a pivotal Phase III trial that demonstrated a 25 % overall response rate and a median progression‑free survival of 7.3 months. The approval also came with a Breakthrough Therapy designation, underscoring the therapeutic promise and expediting post‑marketing studies.

In the oncology pipeline, Mirum is advancing a Phase IIb trial of Mira‑C, a bispecific antibody targeting CD19 and CD22 in B‑cell acute lymphoblastic leukemia. Early data, presented at the 2026 American Association for Cancer Research (AACR) meeting, suggest a 60 % remission rate at 12 months. The trial is set to enter a larger, randomized Phase III study in Q3 2026.

Beyond oncology, the company’s Mira‑X platform, a modular gene‑editing approach using CRISPR‑Cas9 ribonucleoproteins, has entered a Phase I safety study in patients with sickle cell disease. The study aims to evaluate the durability of hemoglobin modification and the incidence of off‑target effects.

Therapeutic Mechanisms and Emerging Treatments

  1. Mira‑B – A selective PI3Kδ inhibitor that interrupts downstream AKT signaling, inducing apoptosis in tumor cells while sparing normal tissues. Its oral bioavailability and manageable safety profile make it an attractive first‑line candidate for combination regimens.

  2. Mira‑C – The bispecific antibody simultaneously engages CD19 and CD22 antigens, enhancing B‑cell depletion while mitigating antigen escape—a common resistance mechanism in CAR‑T therapies.

  3. Mira‑X – Employs a non‑viral delivery system to introduce precise double‑strand breaks at the HBB locus, correcting the β‑globin gene mutation responsible for sickle cell disease. The platform is adaptable to other monogenic disorders.

Investor Takeaways

While Radović’s purchase is modest in scale, it conveys a positive sentiment that aligns with the company’s recent regulatory milestones and robust pipeline. Investors should:

  • Monitor upcoming quarterly earnings for updates on cash burn, revenue generation, and R&D spending.
  • Track clinical milestones for Mira‑B, Mira‑C, and Mira‑X, particularly regulatory filings and FDA communications.
  • Assess the impact of negative earnings on valuation metrics and consider the potential for a market rebound as pipeline data matures.
  • Evaluate insider activity over time to gauge management’s confidence and risk appetite.

In sum, Radović’s March 6 share acquisition, set against the backdrop of Mirum’s regulatory successes and emerging therapeutic candidates, offers a cautiously optimistic signal. Stakeholders are advised to maintain vigilance as clinical outcomes and market dynamics evolve.